Copd new guidelines
Reading File
Finding Sources
Searching PubMed
"COPD" AND "GOLD guidelines"
Searching the Web
GOLD COPD guidelines 2025 2026 new updates
Reading Web Page
https://www.chestphysician.org/gold-2026-updates-in-global-s…
Finding Sources
Searching PubMed
"chronic obstructive pulmonary disease" AND "triple therapy" AND "eosinophil"
Here is a comprehensive summary of the GOLD 2026 COPD Guidelines - the most current update, released November 2025:
GOLD 2026 COPD Guidelines - Key Updates
The GOLD 2026 report is a major revision adding 330 new references (vs. 164 in 2025) from literature published January 2024 - July 2025.
1. Core Conceptual Shift: "Disease Activity"
GOLD 2026 reframes COPD from a static airflow limitation disorder to a biologically active, modifiable disease. The new therapeutic goal is achieving a "low disease activity state" - defined by:
- No exacerbations
- Controlled symptoms
- Minimized disease progression
Spirometry (postbronchodilator FEV1/FVC < 0.70) remains essential for diagnosis but is now interpreted alongside clinical features and imaging.
2. Revised ABE Classification
The classic ABCD tool is now the refined ABE framework:
| Group | Description | Initial Treatment |
|---|---|---|
| A | Low symptoms, low exacerbation risk | Any bronchodilator (monotherapy) |
| B | High symptoms, low exacerbation risk | LABA + LAMA (dual bronchodilation) |
| E | High exacerbation risk (≥1 moderate/severe exacerbation) | LABA + LAMA |
Key change: The threshold for Group E is now any single moderate or severe exacerbation in the prior year (previously required ≥2 moderate OR ≥1 severe). Even one exacerbation is now enough to trigger escalation to dual bronchodilation.
3. Pharmacotherapy Updates
Initial Therapy
- Group A: Single bronchodilator
- Group B & E: LABA/LAMA preferred over LABA/ICS as initial therapy
- LABA/ICS monotherapy is explicitly discouraged without asthma features - it carries higher pneumonia risk and weaker exacerbation prevention vs. dual bronchodilation
Escalation to Triple Therapy (ICS/LABA/LAMA)
Triple therapy is the preferred next step for Group E patients who still exacerbate on LABA/LAMA, guided by blood eosinophil counts (BEC):
| BEC | ICS Recommendation |
|---|---|
| ≥ 300 cells/µL | Strong indication for ICS addition |
| 100-299 cells/µL | Consider ICS |
| < 100 cells/µL | ICS not recommended |
Supported by IMPACT, ETHOS, TRINITY, and TRIBUTE trials. A 2026 meta-analysis (PMID: 42237170) confirms triple therapy superiority over dual therapy for exacerbation reduction.
ICS De-escalation
When risks outweigh benefits, ICS withdrawal is endorsed - but explicitly discouraged if BEC ≥ 300 cells/µL due to high relapse risk.
4. Biologic Therapies - Major Addition
GOLD 2026 formally integrates biologics into the escalation algorithm for the first time at Level A evidence:
- Dupilumab (anti-IL-4/IL-13): For patients with COPD + chronic bronchitis + BEC ≥ 300 cells/µL uncontrolled on triple therapy. Supported by BOREAS and NOTUS trials - reduces moderate-to-severe exacerbations by 30-34% and improves FEV1.
- Mepolizumab (anti-IL-5): Evidence in eosinophilic phenotypes.
A new figure (Figure 3.11) was added specifically outlining biologic therapy evidence.
5. Diagnosis & Case-Finding
- Two new figures added: Figure 2.8 (factors associated with COPD underdiagnosis) and Figure 2.9 (algorithm for COPD case-finding)
- Updated Screening and Case-finding section reflecting new evidence
- Emphasis on early diagnosis beyond symptomatic patients
6. Exacerbation Management
- Updated definitions and severity classifications
- Refined criteria for outpatient vs. inpatient treatment decisions
- High-flow nasal oxygen and noninvasive ventilation now explicitly incorporated
- Structured post-exacerbation follow-up is mandated to reassess and optimize maintenance therapy
- Exacerbation frequency and recovery time are highlighted as markers of disease activity
7. Non-Pharmacological Therapy
- Pulmonary rehabilitation: Reaffirmed as essential; new appendix on non-pharmacological evidence added
- Smoking cessation: Remains the most impactful intervention to slow FEV1 decline
- Vaccinations updated:
- Influenza: Annual vaccination recommended
- RSV vaccination: New recommendation included for people with COPD
- Pneumococcal, COVID-19, and Tdap also recommended
- Lung cancer screening: Annual low-dose CT for patients with smoking history
8. Comorbidities (Revised Chapter)
- Substantially revised chapter on multimorbidity (Chapter 5)
- Common comorbidities: hypertension, ischemic heart disease, HF, atrial fibrillation, bronchiectasis, depression, anxiety
- Comorbidities should be treated per their own guidelines independently of COPD
- A 2025 meta-analysis (PMID: 40684148) on triple therapy shows benefits for cardiovascular mortality in moderate-severe COPD
9. New Chapter: AI and Emerging Technologies (Chapter 6)
A completely new chapter on artificial intelligence and digital health tools in COPD - covering diagnostics, monitoring, and precision phenotyping.
Quick Reference Summary
| Feature | GOLD 2025 | GOLD 2026 |
|---|---|---|
| Group E threshold | ≥2 moderate or ≥1 severe exacerbation | ≥1 moderate or severe exacerbation |
| Biologic therapy | Cautious mention | Level A evidence, integrated into algorithm |
| Disease concept | Airflow limitation | Disease activity as therapeutic target |
| ICS de-escalation | Endorsed | Endorsed, discouraged if BEC ≥300 |
| RSV vaccination | Not mentioned | Recommended |
| AI chapter | Absent | New Chapter 6 |
The full GOLD 2026 report is available at goldcopd.org and the key changes summary from the GOLD Science Committee is a useful quick reference.
This is a shared conversation. Sign in to Orris to start your own chat.